



Acquisition of Elidel completed

Meda's acquisition of global rights for Elidel (*pimecrolimus 1% cream*) – announced on 7 April 2011 - has been completed.

About Elidel

Elidel is a patent protected, specialty focused product for the treatment of atopic dermatitis (AD). Depending on the country, Elidel is indicated as a second-line therapy for the short and long-term management of the signs and symptoms of mild to moderate AD in adults and children two years of age and older.

AD is a chronically relapsing inflammatory skin disease and the skin barrier plays an essential role in protection against AD flares. Elidel is the first non-steroidal topical cream treatment specifically developed for the treatment of AD. To date, Elidel has been studied in more than 60,000 patients. Elidel is approved and sold in more than 90 countries worldwide.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.